Literature DB >> 23318512

F-box only protein 7 gene in parkinsonian-pyramidal disease.

Hao Deng1, Hui Liang, Joseph Jankovic.   

Abstract

Parkinson disease is one of the most common neurodegenerative diseases associated with aging. At least 18 genetic loci and 13 disease-related genes for parkinsonism have been identified. Among them, PARK15 -associated parkinsonism, also referred to as parkinsonian-pyramidal disease (PPD), was found to be caused by mutations in the F-box only protein 7 gene (FBXO7). Parkinsonian-pyramidal disease differs from typical Parkinson disease chiefly by juvenile onset and the presence of spasticity. Four mutations have been identified and a pattern of autosomal recessive inheritance has been proposed in all reported PPD families. The FBXO7 protein is a member of the Skp1-Cullin-F-box-type E3 ubiquitin ligases, which play important roles in targeting proteins for ubiquitination. Although PPD is a relatively rare parkinsonian disorder, understanding its genetic and pathological mechanisms may lead to new insights into the pathogenesis of Parkinson disease and development of therapeutic strategies not only for PPD but also for other parkinsonian disorders.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23318512     DOI: 10.1001/jamaneurol.2013.572

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  19 in total

1.  Systematic Genetic Analysis of the SMPD1 Gene in Chinese Patients with Parkinson's Disease.

Authors:  Sheng Deng; Xiong Deng; Zhi Song; Xiaofei Xiu; Yi Guo; Jingjing Xiao; Hao Deng
Journal:  Mol Neurobiol       Date:  2015-09-16       Impact factor: 5.590

2.  Silencing of SIAH1 in SH-SY5Y affects α-synuclein degradation pathway.

Authors:  Jing Xu; Xin-Zhi Zhang; Yong-Jin Zhang; Xiu-Ming Li; Zeng-Lin Cai; Xiao-Min Li
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

3.  Invasive Treatment Strategies in a Patient with PARK 15-Associated Parkinsonism.

Authors:  Sabine Spielberger; Klaus Seppi; Elisabeth Wolf; Wilhelm Eisner; Werner Poewe
Journal:  Mov Disord Clin Pract       Date:  2015-07-25

4.  Genetic Analysis of FBXO2, FBXO6, FBXO12, and FBXO41 Variants in Han Chinese Patients with Sporadic Parkinson's Disease.

Authors:  Lamei Yuan; Zhi Song; Xiong Deng; Zhijian Yang; Yan Yang; Yi Guo; Hongwei Lu; Hao Deng
Journal:  Neurosci Bull       Date:  2017-03-24       Impact factor: 5.203

5.  Pathophysiology and treatment of neurodegeneration with brain iron accumulation in the pediatric population.

Authors:  Susanne A Schneider; Giovanna Zorzi; Nardo Nardocci
Journal:  Curr Treat Options Neurol       Date:  2013-10       Impact factor: 3.598

Review 6.  Animal models of Parkinson's disease: a gateway to therapeutics?

Authors:  Weidong Le; Pavani Sayana; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 7.  Parkinsonism, movement disorders and genetics in frontotemporal dementia.

Authors:  José Fidel Baizabal-Carvallo; Joseph Jankovic
Journal:  Nat Rev Neurol       Date:  2016-02-19       Impact factor: 42.937

8.  The F-box protein FBXO7 positively regulates bone morphogenetic protein-mediated signaling through Lys-63-specific ubiquitination of neurotrophin receptor-interacting MAGE (NRAGE).

Authors:  Jengmin Kang; Kwang Chul Chung
Journal:  Cell Mol Life Sci       Date:  2014-06-20       Impact factor: 9.261

Review 9.  Recent advances in Parkinson’s disease genetics.

Authors:  Steven Lubbe; Huw R Morris
Journal:  J Neurol       Date:  2014-02       Impact factor: 4.849

10.  Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA).

Authors:  Susanne A Schneider; Petr Dusek; John Hardy; Ana Westenberger; Joseph Jankovic; Kailash P Bhatia
Journal:  Curr Neuropharmacol       Date:  2013-01       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.